NAGE Niagen Bioscience, Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1386570 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.9%
TTM net income YoY-49.9%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR13.6%
Net income 3-yr CAGR—
Margins
Gross margin63.9%
Operating margin3.9%
Net margin8.4%
FCF margin—
EBITDA margin4.3%
Returns
ROE13.3%
ROA9.9%
ROIC (approx.)44.3%
Asset turnover1.18x
Leverage & solvency
Liabilities / assets23.6%
Debt / equity0.00x
Current ratio5.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $27.19M | $29.79M | $31.47M | $33.84M | $33.99M | $31.12M | $30.48M | $29.12M |
| Cost of revenue | $10.09M | $10.47M | $11.50M | $12.13M | $12.06M | $10.89M | $11.15M | $10.93M |
| Gross profit | $17.11M | $19.31M | $19.98M | $21.70M | $21.93M | $20.23M | $19.33M | $18.20M |
| R&D expense | $1.80M | $1.51M | $1.48M | $1.71M | $1.79M | $1.57M | $1.26M | $1.31M |
| SG&A expense | $8.18M | $6.97M | $7.24M | $7.48M | $7.13M | $7.27M | $5.18M | $1.05M |
| Operating income | -$1.59M | $700,000 | $1.58M | $4.09M | $4.24M | $3.19M | $4.77M | $7.11M |
| Pretax income | -$1.17M | $1.07M | $6.74M | $4.42M | $4.80M | $3.74M | $5.23M | $7.48M |
| Income tax | $0 | $106,000 | $417,000 | $292,000 | $222,000 | $128,000 | $168,000 | $305,000 |
| Net income | -$1.17M | $963,000 | $6.32M | $4.13M | $4.58M | $3.61M | $5.06M | $7.18M |
| EBITDA | -$1.47M | $817,000 | $1.69M | $4.22M | $4.39M | $3.34M | $4.93M | $7.26M |
| EPS (basic) | -0.01 | 0.01 | 0.08 | — | 0.06 | 0.05 | 0.07 | — |
| EPS (diluted) | -0.01 | 0.01 | 0.07 | — | 0.05 | 0.04 | 0.06 | — |
| Weighted avg. shares (diluted) | 79.15M | 82.50M | 84.57M | — | 86.62M | 86.24M | 83.23M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $69.51M | $66.74M | $66.55M | $64.79M | $64.29M | $60.47M | $55.62M | $44.66M |
| Receivables | $6.84M | $8.58M | $13.07M | $9.74M | $8.51M | $9.66M | $7.05M | $7.77M |
| Inventory | $20.52M | $20.64M | $24.02M | $20.42M | $18.79M | $14.41M | $11.19M | $9.19M |
| Current assets | $100.22M | $97.79M | $105.12M | $96.81M | $93.62M | $86.68M | $76.22M | $64.10M |
| PP&E, net | $1.22M | $1.25M | $1.30M | $1.32M | $1.50M | $1.63M | $1.66M | $1.72M |
| Intangibles | $5.14M | $5.31M | $5.49M | $5.66M | $246,000 | $284,000 | $322,000 | $359,000 |
| Total assets | $108.69M | $106.59M | $114.33M | $106.41M | $98.14M | $91.53M | $81.34M | $68.28M |
| Current liabilities | $16.91M | $15.05M | $22.82M | $19.92M | $22.71M | $22.33M | $20.84M | $17.95M |
| Total liabilities | $25.62M | $24.06M | $32.00M | $29.87M | $27.46M | $27.33M | $25.99M | $22.18M |
| Shareholders' equity | $83.07M | $82.53M | $82.33M | $76.53M | $70.68M | $64.19M | $55.34M | $46.09M |
| Shares outstanding | 79.03M | 78.91M | 79.46M | 79.71M | 79.64M | 79.59M | 78.43M | 77.33M |
| Cash flow statement | ||||||||
| Operating cash flow | $2.62M | $2.77M | -$1.19M | $679,000 | $3.69M | $1.25M | $7.88M | $8.58M |
| Investing cash flow | -$52,000 | -$92,000 | $5.25M | -$101,000 | -$24,000 | -$135,000 | -$32,000 | -$69,000 |
| Financing cash flow | $196,000 | -$2.49M | -$2.29M | -$80,000 | $148,000 | $3.74M | $3.10M | $3.75M |
| Depreciation & amortization | $115,000 | $117,000 | $116,000 | $139,000 | $157,000 | $158,000 | $158,000 | $151,000 |
| Stock-based compensation | $1.52M | $1.72M | $1.72M | $1.75M | $1.76M | $1.49M | $1.07M | $752,000 |
| Share buybacks | $0 | $2.77M | $2.35M | $251,000 | $0 | $0 | $0 | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.